Miso Kim

机构：Seoul National University, Seoul National University Hospital · ORCID：0000-0002-4064-4199

发表论文 193 篇 · 总被引 5374 次 · h-index 34

代表论文

• Genomic profiling of intimal sarcoma reveals molecular subtypes with distinct tumor microenvironments and therapeutic implications (2025 · ESMO Open · 被引 6)
• Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with leptomeningeal metastases: the KCSG LU 21-01, LAZARUS study (2025 · Lung Cancer · 被引 1)
• A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24) (2025 · Clinical Lung Cancer · 被引 1)
• Predictive role of tumor-infiltrating lymphocytes and immune phenotype for pembrolizumab in relapsed or refractory thymic carcinoma (2025 · Journal of Thoracic Disease · 被引 1)
• The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells (2025 · Cancer Research and Treatment · 被引 1)
• Central Nervous System Activity of Lazertinib in EGFR ‐Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG‐LU20‐15 and LU21‐01 (2026 · Thoracic Cancer)